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Aim: Develop and apply a comprehensive and accurate next-generation sequencing 
based assay to help clinicians to match oncology patients to therapies. Materials 
& methods: The performance of the CANCERPLEX® assay was assessed using DNA 
from well-characterized routine clinical formalin-fixed paraffin-embedded (FFPE) 
specimens and cell lines. Results: The maximum sensitivity of the assay is 99.5% and its 
accuracy is virtually 100% for detecting somatic alterations with an allele fraction of 
as low as 10%. Clinically actionable variants were identified in 93% of patients (930 of 
1000) who underwent testing. Conclusion: The test’s capacity to determine all of the 
critical genetic changes, tumor mutation burden, microsatellite instability status and 
viral associations has important ramifications on clinical decision support strategies, 
including identification of patients who are likely to benefit from immune checkpoint 
blockage therapies.
First draft submitted: 14 February 2017; Accepted for publication: 9 May 2017; Published 
online: 26 May 2017
Keywords:  analytical validation • diagnostics • gene-panels • next-generation sequencing 
(NGS) • precision oncology
Cancer can be caused by a diverse set of genetic 
abnormalities, such as point mutations, gene 
and chromosomal copy number changes and 
structural variants. Some are well known to 
occur within oncogenes or tumor suppressor 
genes that facilitate tumor initiation and pro-
gression while others are less common or less 
well understood. Along with the early discov-
ery of individual cancer driver genes, several 
large-scale genomic studies have annotated 
the broad genomic landscape within com-
mon human tumors and cataloged many 
cancer-associated genomic changes. In par-
allel, a rapidly growing list of cancer drugs 
has been approved for use in patients with 
specific genetic alterations. In addition, an 
avalanche of targeted therapies is currently 
being tested in multiple genomically matched 
clinical trials. Using the genomic profile of a 
patient’s tumor to determine the most opti-
mal treatment protocol is the goal of preci-
sion/personalized medicine, and the salutary 
benefits of such therapies upon survival have 
been well documented [1–4]. The success of 
herceptin (a drug targeting HER2/neu, the 
product of ERBB2 gene) in breast cancers 
with ERBB2 gene amplification [5] has been 
reproduced in many cancers with other 
genetic alterations that are effectively treated 
by targeted therapies [6–8]. Thus, comprehen-
sive genomic profiling is likely to become the 
standard of clinical practice in determining 
the optimal treatment for individual cancer 
patients [9–12].
To address the needs of modern preci-
sion oncology and to realize the benefits of 
routine tumor genome profiling for patients, 
we report utilization of CANCERPLEX®, 
a comprehensive next-generation sequenc-
ing (NGS) based analytical system that can 
identify and prioritize potential treatment 
strategies for solid tumors. CANCERPLEX 
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is based on the rapid and accurate genetic analysis 
of clinical FFPE tissue, including core needle biop-
sies and cell blocks prepared from fine-needle aspira-
tions, malignant pleural effusions and ascites. The 
assay includes efficient extraction of FFPE DNA fol-
lowed by sequencing of 435 important cancer genes 
that are altered in a wide range of solid cancers. The 
assay identifies oncogenic driver events that predict 
response or resistance to treatments and, thus, can 
impact therapeutic strategies. Mutation burden, mic-
rosatellite instability (MSI) and presence of oncogenic 
viruses are additional biomarkers that CANCER-
PLEX can detect, which enables oncologists to reach 
more informed therapeutic decisions. The test was 
developed by KEW, Inc. (Cambridge, MA, USA) to 
support clinical decisions by oncologists. KEW labora-
tory is accredited by the College of American Patholo-
gists (CAP) and has Clinical Laboratory Improvement 
Amendments (CLIA). 
Materials & methods 
Reference material & tumor tissue
For analytical validation of the assay, we used a panel 
of characterized DNA from the HapMap consortium 
(Coriell Institute for Medical Research, NJ, USA), 
cancer cell lines purchased directly from the Ameri-
can Type Culture Collection, and patient tumor and 
normal FFPE samples. Patient FFPE samples consisted 
of discarded and deidentified tumor specimens pur-
chased from BioServe (MD, USA) or obtained from 
clinical operations. Normal FFPE samples of tonsil 
and endometrial tissue were acquired from UMass 
Cancer Center Tissue and Tumor Bank (MA, USA) 
(Supplementary Table 13).
Pathologist review of tissue sections & genomic 
extraction of tumor DNA
For each hematoxylin and eosin stained tissue sec-
tion, regions of high tumor purity were selected for 
macrodissection and the marked hematoxylin and 
eosin slides were then digitally scanned and docu-
mented. For FFPE blocks, tissue macrodissection was 
done using 1-mm biopsy punches. Genomic DNA 
was extracted from tumor tissue using methods pre-
viously described [13]. For quality control (QC) pur-
poses, extracted genomic DNA (gDNA) was evalu-
ated by measuring the A260/A230 ratio (NanoDrop, 
Thermo Fisher Scientific, DE, USA) and by measur-
ing DIN with TapeStation (Agilent Technologies, 
CA, USA). There was no cut-off on DNA Integrity 
Number (DIN) though less gDNA can be used when 
DIN >3.5. The Quant-iT PicoGreen dsDNA Assay 
was used to determine DNA concentration (Thermo 
Fisher Scientific, MA, USA).
Selection of targets
Genes were selected by comprehensive mining of 
the US FDA databases, NCCN, ASCO and ESMO 
Clinical Practice Guidelines in Oncology, COSMIC, 
TCGA and R&D pipelines of large pharmaceutical 
companies. In addition to gene-coding sequences, 
probes were added to address the accurate solving of 
selected chromosomal translocations, broad copy-
number profiling, splice sites and untranslated regions 
(promoter of TERT, 3′UTR of CD274) as well as 
detection of oncoviruses (human papillomavirus 
[HPV] 16, HPV18 and Epstein–Barr virus [EBV]), 
MSI and mutation burden.
Library preparation & Illumina-based NGS
Illumina-NGS ready libraries were produced using 
a proprietary protocol, which utilizes the KAPA/
Roche HyperPlus kit (KK8514, Kapa Biosystems, 
MA, USA). The protocol was optimized for real-world 
clinical specimens to produce DNA fragments in the 
100–200 bp range. Input of gDNA ranged from 50 
to 150 ng. Modifications included the ligation of a 
unique molecular counter. Unique molecular coun-
ters are used to computationally remove sequencing 
artifacts, including PCR duplicates. Prepared libraries 
were tagged with molecular barcodes and individu-
ally enriched for CANCERPLEX genes using custom 
probes. Patient samples were never pooled. Following 
target enrichment, 160-bp sequencing was performed 
using Illumina instruments to 500× mean depth. A 
denatured PhiX library was added to each run as a 
sequencing QC.
Sequence data extraction
For data analysis, we developed a proprietary bioinfor-
matics pipeline that utilizes GATK Best Practices [14]. 
To deal with FFPE-associated biases, a diverse panel of 
normal samples was generated. DNA extracted from 
40 normal, nontumor FFPE tissue specimens was 
sequenced the same way as the clinical samples. The 
resulting panel of normal samples data were used as a 
baseline reference for calling mutations.
Sample QC
Read and base quality score and GC content were 
analyzed with FastQC tool prior to alignment. After 
alignment, QC metrics were calculated for each sample 
including: read counts (total bases, total, unique and 
duplicate reads, mapped and uniquely mapped reads, 
percentages of reads mapped/mapped to the region of 
interest [ROI]); coverage (mean, uniformity, percent-
age of bases with zero coverage); and library complex-
ity. Sequencing data identity was assured by molecular 
barcodes, process controls, and also based on a com-
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posite of tools including determining the percentage 
of concordant single-nucleotide variants (SNVs) with 
respect to previously sequenced samples, inferring sex 
and iAdmix predictions.
Variant calling
SNVs, small insertions and deletions (indels) call-
ing was restricted to genomic regions intended to 
be captured by the assay (ROI). Copy number vari-
ants (CNVs) were called for exons as well as glob-
ally. The threshold for gains was at >2.5-fold and 
for loss at <0.75-fold. Fused genes (structural vari-
ants) were detected if at least one end mapped to any 
of the following genes: AKT3, ALK, BRAF, EGFR, 
ETV1, ETV4, ETV5, ETV6, FGFR2, FGFR3, MET, 
NOTCH1, NOTCH2, NRG1, PDGFRA, RAF1, RET, 
ROS1 and TMPRSS2. Variants were filtered or flagged 
according to technical quality (e.g., coverage, allelic 
fraction, number of supporting reads and strand bias). 
SNVs and indels were annotated using SnpEff and the 
output was adapted per Human Genome Variation 
Society  recommendations.
Other types of analyses
To validate SNVs and indels, pools of highly charac-
terized Coriell DNA samples were prepared with allele 
frequencies ranging from 0.1 to 1.0. The performance 
of the assay was based upon the successful detection 
of the variants known to be present in the Coriell 
samples. To determine whether the depth of cover-
age affects the assay’s sensitivity, a series of diluted 
samples were sequenced in consecutive windows of 
sequencing depth until 200× coverage was reached. 
To validate intra-assay reproducibility and to demon-
strate consistency of test results between different ali-
quots of the same sample and between separate assay 
batches, libraries were prepared from three different 
samples on different days and/or by two different 
operators. Sequencing results were analyzed for  variant 
 concordance.
CNVs and structural rearrangements were validated 
using FFPE tumor samples and cancer cell lines that 
had been previously demonstrated (using FISH, immu-
nohistochemistry (IHC) and/or qPCR) to harbor the 
ERBB2 gene amplification or the EML4-ALK rear-
rangement. The minimum tumor content requirement 
was determined by assessing the impact of sequencing 
depth on the sensitivity of the test to detect the EML4-
ALK gene rearrangement. The H2228 cell line, which 
carries the EML4-ALK gene fusion, was diluted by 
FFPE normal to generate series of samples with a tumor 
content ranging from 0.1 to 0.5. Samples underwent 
multiple sequencing runs and the number of chimeric 
reads as well as overall coverage was determined.
The tumor mutation burden (TMB), defined as 
the rate of peptide-changing SNVs per Mb, was deter-
mined for all tumors. To estimate TMB, SNVs with 
a mutation allelic fraction (MAF) of at least 0.1 after 
standard filtering and with high or moderate putative 
impact were retained.
Determination of MSI was based on an extended loci 
panel. In addition to the Bethesda panel, we analyze a 
collection of up to 950 regions consisting of tandem 
repeats of one, two or three nucleotides of minimum 
length of ten bases. The number of indels within 
the ROI was calculated and tumors were classified 
as high MSI (MSI-H) or microsatellite stable. The 
MSI status of 15 clinical FFPE samples was deter-
mined using PCR to amplify the Bethesda markers 
and IHC to confirm the presence of mismatch repair 
(MMR) proteins. For validation, CANCERPLEX 
testing was performed on the 15 characterized FFPE 
samples and the number of indels within the ROI was 
calculated. Based upon these results, the MSI cut-off 
was set (Supplementary Table 10). Primers for PCR 
validation of MSI status were designed as previously 
described [15]. The PCR was set up using Type-it Mic-
rosatellite PCR Kit by QIAGEN (MD, USA). PCR 
products were resolved by on-chip electrophoresis on 
an Agilent  Bioanalyzer 2100.
Tumors were also analyzed for the presence of 
HPV-16, HPV-18 and EBV (HHV-4) viral sequences. 
The reference genomes used were: GI:310698439, 
GI:9626069 and NC_007605, respectively. The per-
centage of total number of reads mapped to the viral 
genomes was calculated and samples were designated 
as positive based on empirical cut offs of 0.02, 0.01 and 
0.0005% of reads that mapped to HPV-16, HPV-18 
and EBV genomes, respectively. To validate EBV status 
of DNA samples, PCR primers were designed as previ-
ously described [16]. The forward and reverse primer 
sequences for EBV were 5′-CCCGCCTACACAC-
CAACTAT-3′ and 5′-AGTCTGGGAAGACAAC-
CACA-3′. PCR conditions were 95°C for 3 min fol-
lowed by 28 cycles of 98°C for 20 s, 60°C for 15 s and 
72°C for 30 s, followed by the final extension at 72°C 
for 5 min.
Variant assessment in GENEKEEPER
GENEKEEPER is a curation tool and proprietary 
database developed by KEW, Inc. that prioritizes vari-
ants based upon their clinical relevance. Only non-
synonymous variants relative to canonical transcripts 
retrieved from the UniProt database are submitted for 
review. Also, variants were deprioritized if they were 
present under certain conditions (e.g., at allele fre-
quency >1%) in dbSNP, 1000 Genomes, ExAC data-
bases, and then reprioritized with COSMIC. Next, 
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allele frequencies for each mutation were used to fit a 
model to determine whether the variant is likely germ-
line heterozygous or somatic. Finally, results under-
went manual molecular pathologist review validating 
somatic versus possible germline status of a variant as 
described before [17]. The catalog of FDA-approved 
drugs, NCCN treatment guidelines, multiple muta-
tion databases and current scientific literature are addi-
tional resources used to determine if the variant pro-
tein is a target of an FDA-approved drug, a target of 
a drug in clinical development or confers resistance to 
known treatments. Clinical trials are identified using 
the ClinicalTrials.gov and other tools (e.g., Thomson 
Reuter Cortellis and Pharma Intelligence Trialtrove).
Results 
Validation of the assay
We have developed a highly accurate and actionable 
NGS-based cancer diagnostic assay to provide physi-
cians with the genetic information they need to guide 
personalized, patient treatment strategies. The process 
workflow includes the review of tissue specimens by a 
pathologist and the macrodissection of tumor cells in 
specimens with <50% tumor purity (Figure 1A). Probes 
have been custom designed to enrich for genetic mark-
ers that predict response to immuno-oncology drugs as 
well as for genetic alterations that are associated with 
FDA-approved and investigational targeted treatments 
(Figure 1B). Sequencing reagents and protocols have 
been optimized to routinely produce 500× mean cov-
erage from as little as 50 ng of FFPE DNA (Figure 1C). 
We also developed a proprietary bioinformatics pipe-
line with an accuracy of over 99.9% for detecting 
somatic mutations and a custom analysis database that 
is used to match clinically relevant genetic alterations 
with appropriate gene-targeted therapies or clinical 
 trials (Figure 1D).
Most tumor tissue specimens are heterogeneous hav-
ing mixtures of normal and tumor cells, and tumor 
cells might also be mixtures of different subclones. 
Academic studies are often based on highly pure 
tumors and use up to 100× mean coverage of whole 
exomes to detect mutations (TCGA). To identify 
genetic variants that are critical for clinical deci-
sions in ‘real-world’ tumor samples, it is necessary to 
sequence at significantly higher depths. To facilitate 
cost–effectiveness, we examined whether a subset of 
all the coding genes would provide the comprehensive 
information needed for clinical decision support at 
current state of care. After design and testing of several 
subsets, we decided upon a panel including 435 genes 
to profile for genetic changes in solid tumor samples 
(Supplementary Table 1 for the list of genes). This test 
is called CANCERPLEX. These genes are known to 
have somatic alterations in one or more tumor types 
(Figure 2A & Supplementary Table 14). The 435 genes 
include all clinically relevant targets of FDA-approved 
therapies, targets of investigational therapies in current 
clinical trials, DNA repair genes, cancer biomarkers 
and targets of prospective clinical trials (Figure 2B). 
CANCERPLEX protocols and reagents were opti-
mized to maximize sequencing uniformity and depth 
of coverage across ROI (Supplementary Table 15). 
The average coverage for the targeted sequences is 
500× (Supplementary Figure 1A) and the major-
ity of sequenced bases (∼80%) were aligned to ROI 
(Supplementary Figure 1B). Sequencing libraries pro-
duced uniform coverage, regardless of the regional GC 
content, (Supplementary Figure 1C), and high coverage 
was attained across all 435 genes that are part of the 
panel (Supplementary Figure 2).
We developed the gene panel assay with the goal 
of identifying all the genomic features that inform 
treatment decisions and with the highest possible 
accuracy. We have thoroughly evaluated the per-
formance of the assay using reference samples that 
represent all classes of genetic variation, including 
SNPs, indels, CNVs, rearrangements, HPV/EBV and 
MSI. FFPE clinical samples were also included to 
assess the ability of the assay to detect genetic varia-
tion in complex and heterogeneous tumors. We cre-
ated a series of samples with mutant allelic fractions 
(MAF) ranging from 0.1 to 1.0 and found that the 
assay has excellent performance with a mean sensitiv-
ity of 99.5% and accuracy of 99.9% to detect SNPs 
with MAF = 10% (Supplementary Table 2). Indels 
with an allelic fraction of 10% were detected with 
a mean sensitivity of 100% and accuracy of 100% 
(Supplementary Table 3). For cancer cell lines that were 
independently validated by Sanger sequencing, the accu-
racy was similarly high at 98.7% for SNPs and 100% 
for indels (Supplementary Tables 4 & 5). The variant 
allele fraction as determined by CANCERPLEX cor-
related with expected results (Supplementary Table 6). 
The results of inter- and intra-assay reproducibility 
studies revealed a high level of precision; the con-
cordance between replicate samples was 92.3–97.7% 
(Supplementary Table 7). The minimum tumor con-
tent requirement was determined by assessing the 
impact of sequencing depth on the sensitivity of the 
assay to detect SNVs. For tumor purity 20%, accept-
able high sensitivity detection of SNVs (>98%) was 
achieved when coverage was increased to between 
150 and 200× (Supplementary Table 8), setting the 
minimum requirement of tumor content at as low as 
20%. We routinely use 500× coverage for the clinical 
samples.
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Figure 2. Selection of CANCERPLEX® targets (see facing page). (A) Heat map depicting the mutation frequency 
of the 435 genes on the CANCERPLEX gene panel across 31 different cancer types (y-axis). Red indicates genes 
with the highest mutation frequencies (1÷0.05) and blue indicates genes with lower mutation frequencies. Genes 
with the highest and lowest overall mutations frequencies are shown on the x-axis. (B) Venn diagram showing the 
different categories of clinically relevant cancer genes that make up the gene panel. The number of genes that are 
represented in each category are shown and the overlaps represent the union of sets (total number less double 
counting).
Figure 3. Tumor types across 1000 clinical samples tested. The percentage of tumors of each type is provided.
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Characteristics of tumor specimens
We have examined 1000 clinical samples sent from 
diverse groups of oncologists. We were able to extract 
adequate amounts of DNA from different types of sam-
ples, including FFPE blocks, core biopsies, fine-needle 
aspirations and effusions. The majority of the specimens 
were derived from advanced stage tumors (T4, 78%), 
while the remaining tumors were either unknown 
stage (TX, 14%) or from less advanced stage tumors 
(8%). We examined samples from lung cancer (31%), 
colorectal cancer (35%), gastric and esophageal cancer 
(15%) and breast cancer (9%). All other tumor types 
 constituted the remaining 20% of tumors (Figure 3).
Genetic alterations detected by CANCERPLEX
CANCERPLEX is an assay that uses NGS data to 
determine many different types of somatic genetic 
changes in tumors. The types of changes that could be 
detected are shown in Figure 4. All tumor samples had 
somatic mutations. Among point mutations, missense 
mutations were the most frequent (81%), while muta-
tions that result in indels or prematurely truncated 
proteins made up the vast majority (18%) of remaining 
mutations. (Figure 4 top, left panel).
We have developed analytical methods to detect copy 
number alterations in oncogenes, such as ERBB2, and 
tumor suppressors, such as CDKN2A. (Figure 4 top, 
middle panel). Results of validation testing revealed 
that the detection of key pathogenic CNVs was 
highly concordant with results obtained using stan-
dard techniques, including qPCR and FISH (Table 1 
& Supplementary Table 9). Additionally, we show that 
the global CNV profile generated by CANCERPLEX 
is consistent with the profile generated by the Affyme-
trix SNP 6.0 array (Supplementary Figure 3A & B). 
We used IHC testing to confirm that a focal deletion 
detected in glioblastoma tumor cells at the 9p21.3 loci 
correlated with lack of CDKN2A staining and that 
a focal amplification in colorectal tumor cells at the 
17q13 loci correlated with positive staining for the 
HER2 protein (Supplementary Figure 3C–F). Taken 
together these results affirm the power of the assay to 
detect cancer-associated CNVs.
Chromosomal rearrangements occasionally result in 
the formation of functional hybrid proteins that drive 
tumorigenesis. The assay was able to detect a number 
of rearrangements that have been previously shown to 
produce oncogenic fusion proteins, such as ALK and 
ROS [18,19] as well as several rearrangements that have 
not been reported previously but which are likely to 
produce functional gene fusions (Figure 4 top, right 
panel). A schematic representation of a CD47-MET 
gene rearrangement and the predicted fusion protein 
consisting of the N-terminal region of the CD47 pro-
tein and the kinase domain of the MET protein is 
shown in Figure 5.
MSI is due to the inactivation of MMR genes, such as 
MLH1 and MSH2, resulting in the loss or gain of short 
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Figure 5. CD47-MET gene rearrangement and formation of a potentially functional gene fusion protein. The genomic structure 
surrounding the breakpoint within the intron 14 of the MET gene and intron 7 of the CD47 gene is shown. A chromosomal inversion 
leads to fusion of intron 7 of the CD47 gene to intron 14 of the MET gene. The domain organization of each protein is shown as well 
as the domain structure of the predicted fusion protein. The sequence surrounding the protein fusion site is predicted to be in-frame 
and is shown below.
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tandem DNA repeats (microsatellite repeats) [20,21]. 
The CANCERPLEX assay utilizes 950 microsatellite 
repeats including markers that are currently used in 
a clinical setting, and thus has great statistical power 
to identify tumors that exhibit MSI (Figure 4 bottom, 
middle panel). Independent testing methods, including 
Table 1. Orthogonal validation of CANCERPLEX results.
Type of independent 
testing
Tested by Detected by 
CANCERPLEX
Concordant/
tested 
samples
Concordance Comments on discordant cases
KRAS hotspot variants PCR SNVs 18/19 95% Different variant detected at the same 
codon
NRAS hotspot variants PCR SNVs 2/2 100%  
BRAF hotspot variants PCR SNVs 7/7 100%  
EGFR hotspot variants PCR SNVs/indels 29/29 100%  
Expression of DNA 
MRR enzymes
IHC SNVs and indels 
in MRR genes
43/43 100%  
Her2 amplification FISH/IHC ERRB2 gain 
(CNV)
78/83 94% Different specimens tested (different 
timepoints, after treatment) or ERBB2 
gain detected below cut-off (tumor 
heterogeneity)
MET amplification FISH MET gain (CNV) 1/1 100% –
ALK rearrangement FISH, PCR ALK 
rearrangement
24/24 100% –
ROS1 rearrangement FISH ROS1 
rearrangement
9/9 100% –
The detected 217 key driver events are highly concordant with results obtained using techniques other than Illumina NGS. Samples underwent CANCERPLEX testing 
and the concordance between methods was then determined.
CNV: Copy number variant; IHC: Immunohistochemistry; indel: Insertion and deletion; MRR: Mismatch repair; NGS: Next-generation sequencing;  
SNV: Single-nucleotide variant.
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Figure 6. Clinical validity of CANCERPLEX®. (A) Percentage of 1000 tumors in which clinically relevant mutations were detected. 
(B) The 20 most frequently mutated genes in 211 NSCLC adenocarcinoma tumors are shown. Dark bars denote the total number of 
mutations detected in each gene, light blue bars depict only pathogenic or likely pathogenic mutations. 
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IHC and/or PCR were used to determine the MSI status 
of a subset of colorectal patients. The CANCERPLEX 
test correctly identified the MSI status of every colorec-
tal patient, with the same sensitivity as IHC but with 
greater sensitivity than PCR (Supplementary Table 10). 
The limit of detection was determined to be 10% 
tumor content, based upon results of tests from samples 
spiked with serial dilutions of a MSI-H tumor DNA 
(data not shown).
The TMB, defined as the rate of SNVs per Mb, can 
be determined from data generated from either whole-
exome sequencing (WES) or targeted-gene panels [22,23]. 
MMR deficiency is found in roughly 15–20% of spo-
radic colorectal cancers (MSI-H colorectal cancers) 
and those resulting from germline mutations leading 
to hereditary nonpolyposis colorectal cancer or Lynch 
syndrome [24]. Tumors that exhibit MMR deficiency 
harbor hundreds to thousands of mutations, whereas 
MMR-proficient tumors typically have dozens [21]. The 
TMB and MSI status was determined for 262 colorec-
tal tumors sequenced using CANCERPLEX and the 
results are shown in Figure 4 bottom, left panel.
CANCERPLEX includes probes that correspond to 
HPV and EBV biomarkers. Infection with these agents 
confers an increased risk of developing several different 
types of cancer, including head and neck and cervical 
cancer [25,26] and have implications on tumor classifi-
cation, prognosis and treatment strategies [27,28]. The 
proficiency of the assay to detect these viruses was eval-
uated by testing a set of previously characterized virus-
positive and -negative human DNAs, including clinical 
FFPE tumors, HeLa cells and two DNA samples derived 
from EBV-transformed cell lines. Results of validation 
testing demonstrated that the assay correctly identified 
EBV and HPV16/18 status in 100% of tested samples 
(Figure 4 bottom, right & Supplementary Table 11) and 
based on in silico dilutions, we established the limit of 
detection at 5% tumor content.
Clinical relevance
We assessed the usefulness of the 435-gene panel in 
two ways. First we used the TCGA data to compare 
the mutations in genes obtained by WES and from 
the 435-gene panel. We found that all cancer gene 
mutations that could be detected by WES were also 
detected by the 435-gene panel and at a comparable 
mutation frequency across a wide range of tumor types 
(Figure 2A). Second, the genetic/genomic profile gener-
ated by CANCERPLEX was used to assess potential 
therapeutic opportunities for the patients. We find that 
the results from 93% of the samples are actionable in 
determining an optimal clinical treatment decision 
for the patient (Figure 6A). Actionability is defined as 
having a genetic change for which there is either an 
FDA-approved therapy for the patient’s disease or a 
different disease or therapies in clinical development. 
Aberrations that influenced therapeutic decisions, for 
example, by conferring resistance to therapies, are also 
reported.
In the clinical settings, if the detected pathogenic 
variant is coming from the ‘cancer risk’ gene group 
(e.g., BRCA1, BRCA2 and Lynch Syndrome genes), 
CANCERPLEX reporting system recommends a 
retest using dedicated genetic counseling services. 
We have examined the genetic changes in two of the 
tumor types with the largest number of specimens. In 
non-small-cell lung carcinoma (NSCLC) adenocar-
cinoma, mutations were most frequently detected in 
TP53, KRAS, ARID1A and FAT1 (Figure 6B). These 
results are consistent with TCGA data [29]. Pathogenic 
variants associated with targeted therapies that were 
detected in the highest percentage of NSCLC patients 
include TP53 (48%), KRAS (27%), STK11 (17%) and 
EGFR (11%) (Figure 6C). In colorectal tumors, muta-
tions were most frequently detected in APC, TP53, 
KRAS and KMT2D. (Figure 6D). These results are also 
consistent with TCGA data [30]. In addition, we identi-
fied multiple genes in the PI3K-AKT-MTOR signal-
ing pathway that were predicted to promote constitu-
tive pathway activation (Figure 6E). MTOR-targeted 
inhibitors, including the FDA-approved drug evero-
limus, block the tumor-promoting signals generated 
by mutations in each of these genes. Many additional 
drugs that target each node of the PI3K-AKT-MTOR 
pathway are currently being evaluated in clinical tri-
als to treat patients with aberrant PI3K-AKT-MTOR 
signaling [31].
Using TMB & MSI to predict candidates for 
immunotherapy
CANCERPLEX detects all mutations in the 435 genes 
as well as in confirmed microsatellite loci. This infor-
Figure 6. Clinical validity of CANCERPLEX (cont. from facing page). (C) The ten genes in NSCLC adenocarcinoma 
that had the highest frequency of pathogenic or likely pathogenic mutations are presented on the x-axis. The 
percentage of NSCLC adenocarcinoma tumors that harbored pathogenic or likely pathogenic mutations in each 
gene is presented on the y-axis. (D) The 20 most frequently mutated genes in 262 CRC tumors are shown. Dark 
bars denote the total number of mutations detected in each gene, light blue bars depict only pathogenic or likely 
pathogenic mutations. (E) The ten most frequently mutated genes in CRC that are either known to or predicted to 
activate the PI3K-AKT-MTOR pathway.
CRC: Colorectal cancer; NSCLC: Non-small-cell lung carcinoma.
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Figure 7. Microsatellite instability and tumor mutation burden readouts. (A) 15 colorectal tumors, whose MSI 
status had been previously determined, underwent CANCERPLEX testing (Supplementary Table 9). The number 
of indels was calculated for each tumor and based upon these results, the MSI threshold was set (dashed line). 
(B) Mutation burden as calculated by a 435-gene panel (CANCERPLEX; x-axis) correlates with mutation burden 
as calculated by WES (y-axis). (C) ROC analysis of CANCERPLEX for CRC responders versus nonresponders to 
pembrolizumab (downsampling published data [35]). Red dashed line ROC curve using WES data, blue line ROC 
curve using data produced from CANCERPLEX testing. (D) Predictive accuracy of CANCERPLEX-mutational load 
(y-axis) for durable clinical benefit is comparable to that estimated by WES (downsampling published data [35]). 
Progressive disease, stable disease, partial response.
CRC: Colorectal cancer; indel: Insertion and deletion; MSI: Microsatellite instability; ROC: Receiver operating 
characteristic; WES: Whole-exome sequencing.
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mation can be used to deduce the mutation burden 
and the MSI status in each tumor (Figure 7A). It has 
been shown that TMB can be used to identify patients 
who are more likely to respond to immune checkpoint 
inhibitors that target programmed death 1 (PD-1) 
or PD-L1 [32,33]. Le et al. has shown previously that 
TMB, as determined by WES, correlated with how a 
cohort of 16 patients with advanced cancer responded 
to pembrolizumab [35]. Additional studies have shown 
that panel-based tumor sequencing can predict the 
hypermutated phenotype as accurately as WES [23,34]. 
To determine if mutation burden, as determined by the 
gene panel, also predicts response to checkpoint inhibi-
tors, we performed downsampling on the WES data 
provided by Le et al., including only the 435 genes repre-
sented on CANCERPLEX, and found that assessment 
of TMB using the 435 gene panel correlated with the 
results obtained using WES and accurately predicted 
response to pembrolizumab (Figure 7B–D). Among the 
tested cohort of 262 colorectal cancer patients, 25.7% 
qualified as candidates for  immunotherapy based upon 
TMB/MSI results.
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Gene fusions provide an opportunity for 
precision medicine
Gene rearrangements can result in the expression of 
fusion proteins that drive tumors with unique clinical 
features [36–38]. Patients harboring tumors that express 
oncogenic fusion proteins tend to be particularly sensi-
tive to targeted inhibition of the fusion protein. For 
instance, the tyrosine kinase inhibitor (TKI) crizo-
tinib is approved to treat ALK-positive NSCLC based 
upon results of clinical trials demonstrating superior 
progression-free survival and response rates compared 
with standard chemotherapy [39,40]. Importantly, tar-
geted inhibitors of the ALK and ROS1 kinases are 
approved for NSCLC patients with tumors that express 
these gene fusions, while a number of other targeted 
drugs are approved for other indications. We designed 
probes that target intronic regions flanking previously 
reported breakpoints for 19 oncogenes involved in 
genomic rearrangements that are likely to have clini-
cal implications. Validation testing using DNA from 
cell lines expressing the EML-ALK gene fusion demon-
strated that results from the CANCERPLEX assay 
were highly concordant with results obtained using 
FISH and that the assay’s sensitivity and accuracy to 
detect the EML4-ALK gene rearrangement was 100% 
(Supplementary Table 9). We performed a limit of 
detection and linearity analysis and found that fusion 
junction points were detected with 100% accuracy 
when tumor cellularity was ≥20% and mean cover-
age was at least 300× (Supplementary Table 12). Out 
of the 238 NSCLC cases that underwent CANCER-
PLEX testing, ALK, ROS1 or RET gene fusions were 
detected in 5.0% (12 of 238), which is similar to the 
reported frequency of these three gene fusions in lung 
 adenocarcinoma [41–43].
Case studies
NGS-based comprehensive tumor profiling enables the 
identification of therapeutically actionable mutations 
in tumor types they are not commonly associated with. 
For instance, we detected a BRAF-V600E mutation in 
a patient with rhabdoid meningioma. Importantly, 
dabrafenib, a BRAF-V600 specific inhibitor, has 
been used previously with impressive results to treat 
a child with BRAF-mutant positive rhabdoid menin-
gioma [44]. In a patient with melanoma, we identified 
a less common mutation in the BRAF gene (BRAF-
L597R). Although the BRAF-V600 specific drugs 
dabra fenib and vemurafenib and the MEK inhibitor 
trametinib are not approved to treat patients with 
BRAF non-V600 mutations, there are two case reports 
that describe significant clinical response to vemu-
rafenib and trametinib in patients with BRAF-L597R 
mutant melanoma [45,46].
NGS-based comprehensive tumor profiling tests 
enable clinicians to optimize patient treatments by iden-
tifying therapeutically relevant mutations that would 
be missed if pathology-based classifications, individual 
gene testing, hot-spot testing or small panels were used. 
Tumor mutation profiling can also be important for 
patients that are likely to acquire mutations that confer 
resistance to standard therapies. For instance, we identi-
fied androgen receptor mutations in prostate cancers that 
act as agonists in the presence of enzalutamide (H875Y 
and T878A) or bicalutamide (W742C) and that confer 
resistance to bicalutamide (S889G). In a single patient 
with castrate-resistant prostate cancer, three mutations 
were detected that have previously been shown to cause 
acquired resistance to bicalutamide and enzalutamide 
treatments [47]. Patients with acquired drug resistance 
mutations may retain sensitivity to alternative treat-
ments. Patients expressing the W742C mutation, for 
example, remain sensitive to the antiandrogen, hydroxy-
flutamide [48]. Hormone therapies are also commonly 
prescribed to patients with ER-positive breast cancer, 
however, 30% of these patients exhibit de novo resis-
tance and significantly more patients will acquire resis-
tance [49,50]. Several mutations found in the ESR1 gene 
confer resistance to aromatase inhibitors while retaining 
sensitivity to antiestrogen treatments [51–53]. We identi-
fied three mutations, Y537N, D538G and E380Q, that 
confer this type of selective endocrine resistance in 9.5% 
of ER-positive breast cancers.
Trastuzumab, a monoclonal antibody against the 
ERBB2 (HER2) receptor that was first approved by 
the FDA to treat a subset of patients with ERBB2-over-
expressing breast cancer is now approved, in combina-
tion with chemotherapeutic agents, to treat metastatic 
gastric or gastroesophageal junction adenocarcinoma. 
ERBB2 can also be activated by somatic mutations that 
cause constitutive kinase activity [54]. However, unlike 
ERBB2 amplifications, ERBB2 gain-of-function muta-
tions would be missed by methods used in pathology 
labs to classify the ERBB2 status of breast tumors. We 
have detected previously described ERBB2-activating 
mutations in several cases of breast, colorectal, gastro-
esophageal and lung cancers and in single cases of 
cervical, bladder and small intestinal cancer. Impor-
tantly, FDA-approved, small molecule TKIs that target 
the ERBB2 protein have shown promise in clinical 
trials to treat lung adenocarcinoma patients with 
 ERBB2-activating mutations [55,56].
Discussion
Our understanding of the biology of many types of 
cancer is significantly enhanced by our understand-
ing of the genetic/genomic changes in tumors. Use of 
genetic testing is often required prior to prescribing 
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drugs (e.g., EGFR TKIs for certain NSCLC, crizotinib 
for NSCLC patients with ALK or ROS rearrangements), 
and testing can help the development of optimal ther-
apies for a large number of tumors. NGS-based com-
prehensive tumor profiling provides the essential basis 
for obtaining the information to make such therapeutic 
decisions. A major obstacle to the success of these assays 
is reaching the sensitivity and specificity levels required 
to make reliable variant calls from clinical specimens 
that are often of dubious quality, quantity and/or tumor 
content. The CANCERPLEX assay has overcome these 
challenges by adopting a robust workflow that includes 
dissecting regions of the FFPE specimen enriched for 
tumor cells, customizing reagents and protocols to aug-
ment the sensitivity and specificity of the assay, sequenc-
ing data analysis pipeline to efficiently filter out tech-
nical artifacts and to extract clinically relevant features. 
CANCERPLEX demonstrated sensitivity of 99.5% and 
specificity of 99.9% for MAF ≥0.1. Detection of key 
oncogenic CNVs and chromosomal rearrangements 
was 100% concordant with the results obtained using 
 independent well-established techniques.
The 435-gene panel provides significant advantages 
over individual gene testing, hot-spot testing or small 
panels. For instance, in 4 colorectal and 8 CNS tumors 
that had been previously characterized as wild-type 
using a small targeted gene panel, 30 additional clini-
cally actionable mutations were identified in 9 of the 
12 tumors using the 435-gene panel [57]. Importantly, 
expanded gene panels also enable the identification of 
additional genetic/genomic events, including TMB and 
MSI status, that may provide patients with  treatment 
options that would have otherwise been missed.
The ability to mobilize an individual patient’s immune 
system to treat cancer has long been a goal and that goal 
is now being recognized with the approval of several 
drugs that can stimulate the immune system for treating 
several different cancers [58]. Identifying biomarker(s) 
that predict which cancer patients will respond to check-
point inhibitors is essential. PD-1 and its ligand (PD-L1) 
are the targets of most immune checkpoint drugs and 
PD-L1 expression is commonly used as a biomarker 
for selecting patients who are most likely to respond to 
immunotherapy [59]. More recent clinical data have dem-
onstrated that PD-L1 expression alone is insufficient to 
accurately predict patient response to immune-oncology 
drugs [60]. TMB and DNA repair deficiencies (MSI) 
have evolved as more reliable biomarkers for selecting 
candidates for immuno therapy [35,61,62]. Virus-associ-
ated tumors express neo-antigens making these tumors 
additional, excellent targets for immunotherapy [63].
The CANCERPLEX assay was designed to facilitate 
the identification of cancer patients most likely to respond 
to immunotherapies by incorporating probes that detect 
amplification of the PD-L1, PD-L2 and JAK2 gene locus 
(9p24.1), regions of DNA implicated in MSI and inte-
gration of the HPV and EBV viral genomes. Addition-
ally, we have adopted a formula that utilizes only highly 
informative, nonsynonymous mutations to calculate 
TMB. We have found that calculating TMB using the 
comprehensive gene panel predicts response to pembro-
lizumab just as effectively as using WES. The inclusion 
of these predictive biomarkers in comprehensive tumor 
profiling will enable the identification of patients who are 
likely to achieve significant benefit from immunotherapy 
who would have otherwise been missed.
Conclusion
Herein we report our experience with CANCERPLEX, 
an NGS-based assay that can accurately identify action-
able genomic alterations within a clinically reasonable 
turnaround time and, thus, could guide personalized 
treatment strategies in upto 93% of clinical cases. Our 
methodology successfully addresses the challenges of 
sequencing samples with limited tumor content or 
low purity. CANCERPLEX was designed as a high-
performance assay that leverages all clinically relevant 
information derived from genomic profiling to generate 
personalized patient reports. The benefit of adopting 
comprehensive molecular profiling into routine cancer 
care is a reality for common cancers and continues to 
expand to additional tumor types as knowledge is gained 
from a broad spectrum of targeted clinical trials.
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